AIM ImmunoTech Inc. Highlights Study Linking COVID-19 to Increased Risk of ME/CFS and Ampligen's Potential as a Therapeutic Solution

A study links COVID-19 infection to higher ME/CFS rates, supporting Ampligen's potential as a treatment for affected individuals.

Quiver AI Summary

AIM ImmunoTech Inc. has commented on a recently published study in the Journal of General Internal Medicine that indicates a strong link between COVID-19 and increased rates of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), noting that the incidence among COVID-19 infected individuals is significantly higher than pre-pandemic levels. The study revealed that 531 out of 4,515 participants developed ME/CFS, translating to a prevalence rate of 4.5%, much greater than those who were not infected. AIM is focusing on the development of its antiviral drug, Ampligen, as a potential treatment for ME/CFS and Long COVID, with positive results from clinical trials suggesting that early administration may lead to significant improvements in patients. AIM's CEO emphasized the need for attention to these chronic conditions, especially in light of the pandemic, and highlighted Ampligen's potential to address this pressing health issue.

Potential Positives

• The commentary on the article reinforces AIM ImmunoTech's strategic focus on Ampligen as a treatment for ME/CFS and Long COVID, highlighting the drug's potential therapeutic benefits in a growing market.
• The reported data shows a significant prevalence of ME/CFS among COVID-19 survivors, emphasizing the public health need for effective treatments like Ampligen, potentially increasing its market demand.
• The positive results from the AMP-518 clinical program provide strong support for the efficacy of Ampligen, contributing to confidence in the drug's therapeutic potential and aiding in future trial designs.
• AIM's proactive pivot to research and clinical studies on Long COVID positions the company favorably within the pharmaceutical industry as it addresses emerging health challenges post-pandemic.

Potential Negatives

• The press release emphasizes the significant health crisis associated with ME/CFS and Long COVID, potentially highlighting AIM ImmunoTech's limited ability to effectively address these severe conditions.
• Forward-looking statements caution investors about risks and uncertainties, indicating that there is no guarantee that Ampligen will be approved as a therapy, which may undermine investor confidence.
• The high prevalence of ME/CFS following COVID-19, as revealed in the study, may reflect broader public health challenges that AIM ImmunoTech is striving to address, but it also suggests the possibility of increased scrutiny on their solutions and effectiveness.

FAQ

What does the study link between COVID-19 and ME/CFS reveal?

The study shows a 15-fold increase in ME/CFS incidence among SARS-CoV-2 infected participants compared to pre-pandemic rates.

How does Ampligen benefit patients with Long COVID or ME/CFS?

Ampigen has shown potential therapeutic effects, improving fatigue symptoms and physical performance in clinical studies of post-COVID patients.

What was the prevalence of ME/CFS in the study's participants?

The study found a ME/CFS prevalence of 4.5% among those infected with SARS-CoV-2, significantly higher than uninfected individuals.

When is the best time to administer Ampligen for ME/CFS treatment?

Early treatment with Ampligen may lead to significant improvements, particularly for patients with symptom durations of less than eight years.

Where can I find more information about AIM ImmunoTech and Ampligen?

For more details, visit AIM ImmunoTech's website or check ClinicalTrials.gov for information on the AMP-518 trial.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$AIM Insider Trading Activity

$AIM insiders have traded $AIM stock on the open market 10 times in the past 6 months. Of those trades, 9 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $AIM stock by insiders over the last 6 months:

• THOMAS K EQUELS (CEO & President) has made 6 purchases buying 212,837 shares for an estimated $44,511 and 0 sales.
• STEWART APPELROUTH has made 3 purchases buying 93,065 shares for an estimated $18,172 and 0 sales.
• WILLIAM M MITCHELL sold 4,580 shares for an estimated $883

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$AIM Hedge Fund Activity

We have seen 13 institutional investors add shares of $AIM stock to their portfolio, and 11 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• CITADEL ADVISORS LLC added 359,740 shares (+367.0%) to their portfolio in Q3 2024, for an estimated $97,129
• ARMISTICE CAPITAL, LLC added 252,000 shares (+6.2%) to their portfolio in Q3 2024, for an estimated $68,040
• TWO SIGMA SECURITIES, LLC removed 125,003 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $33,750
• BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 77,900 shares (-87.6%) from their portfolio in Q3 2024, for an estimated $21,033
• GEODE CAPITAL MANAGEMENT, LLC added 62,989 shares (+15.7%) to their portfolio in Q3 2024, for an estimated $17,007
• XTX TOPCO LTD added 51,371 shares (+353.6%) to their portfolio in Q3 2024, for an estimated $13,870
• VIRTU FINANCIAL LLC added 45,929 shares (+81.7%) to their portfolio in Q3 2024, for an estimated $12,400

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS

The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response, offering potential therapeutic benefits for people with ME/CFS or Post-COVID chronic fatigue

OCALA, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) --


AIM ImmunoTech Inc.



(NYSE American: AIM)

(“AIM” or the “Company”) today offered commentary on a new article in the

Journal of General Internal Medicine

linking COVID-19 to increased risk of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”).

The article, titled “

Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study

,” found that among study participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates. The article’s lead author, Suzanne D. Vernon, PhD, emphasized the following highlights in an

accompanying analysis

posted to the Bateman Horne center website:

• 
  Of the 4,515 participants who enrolled within 30 days of contracting COVID-19, 73 developed ME/CFS at least six months post-infection.
  


• 
  In total, 531 participants met ME/CFS criteria, translating to a prevalence of 4.5% among those infected—nearly eight times higher than uninfected participants.
  


• 
  This prevalence is five times higher than pre-pandemic estimates and underscores the severe and lasting impact of COVID-19 on public health.
  


• 
  90% of these post-COVID-19 ME/CFS cases clustered with the most symptomatic and severe cases of Long COVID, highlighting the overlap between these two conditions.
  

Dr. Vernon stated in her commentary: “This finding reinforces what we at [Bateman Horne Center] have long known: ME/CFS is not only a real and diagnosable condition, but it is also a disabling disease that demands attention, especially in the wake of a global pandemic.”

Ampligen in ME/CFS and Long COVID

This new detailed analysis supports AIM’s scientific and business decision to emphasize the development of its drug Ampligen as a treatment for people suffering from ME/CFS symptoms post-COVID-19. AIM had extensive experience with ME/CFS prior to the COVID-19 pandemic and was able to quickly pivot to research and clinical studies on Long COVID; the

RECOVER

ME/CFS data supports this move.

In September 2024, AIM announced

that analysis of the complete clinical patient data from its AMP-518 clinical program supported the Company’s belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would therefore likely be the subject population for a planned follow-up clinical trial.

AMP-518 analysis determined that study patients with Long COVID were, on average, able to walk farther in a Six-Minute Walk Test (“6MWT”) when compared to subjects who received a placebo. The 6MWT measured the distance a subject was able to walk in six minutes as a baseline and then again at 13 weeks. A clear signal of significant potential (p <0.02, two-tailed T-test) was observed in Ampligen-treated subjects with a baseline 6MWT less than 205 meters, who saw a mean improvement of 139 meters, compared to a mean improvement of 91 meters in the corresponding part of the group who received the placebo. AIM therefore believes that any future trial design should focus on Ampligen’s therapeutic potential for subjects who’s Long COVID-related fatigue can be categorized as moderate or worse.

AIM CEO Thomas K. Equels stated: “Based on our previous data of Ampligen in ME/CFS and the strong similarities to long-term symptoms of COVID, expanding the use of Ampligen for the treatment of Long COVID was a natural next step. That expansion of our pipeline of studies at the onset of the pandemic has proven to be a successful venture with the positive results from our Phase 2 study of people with the Post-COVID condition of fatigue. We continue to be encouraged by Ampligen’s ability to improve measures of fatigue and believe that these advances will translate into advancement in the treatment of ME/CFS given the high correlation of symptoms with Long COVID. The recently published article further supports the link between Long COVID and the incidence of ME/CFS, and bolsters our confidence in the potential of Ampligen to address this growing unmet need.”

Ampligen as an Early-Onset Therapy

Data published in


PLOS One


in 2020 detailed how Ampligen could have a considerable positive impact on people living with ME/CFS when administered in the early stages of the disease. The ME/CFS population of 208 subjects was divided into two subsets based on symptom duration. The Target subset consisting of 75 patients with ME/CFS symptom duration of 2-8 years was compared to a Non-Target subset consisting of 133 patients with symptom duration outside of the 2-8-year range.

The placebo-adjusted percentage increase in Exercise Treadmill Testing (“ETT”) and the vertical rise in feet while exercising on the treadmill in the Target subset were both at least twice that seen for the combined population of 208 subjects. While no clinically significant ETT response was seen in the Non-Target subset, within the Target subset, 51.2% of the Ampligen-treated subjects improved their exercise duration by at least 25% (p=0.003, a statistically significant value). This magnitude of exercise improvement was associated with additional measures of improved quality of life, including an ability to ascend the equivalent of nearly 175 more vertical feet at Week 40 when compared to the baseline value before the Ampligen treatment was started. The analysis indicates that there may be a relatively short disease duration window early in the course of the disease (before eight years) in which ME/CFS patients may see a significant clinical response.

Equels states: “Early treatment may make a life-changing difference. We cannot afford to lose another generation to the ravages of ME/CFS.”

AIM Consulting Medical Officer Charles Lapp, MD, stated: “The PLOS One data demonstrated the potential for a significant therapeutic advantage for ME/CFS patients who receive Ampligen in the earlier stages of the disorder. This would be especially significant for those suffering most severely, as ME/CFS can become totally debilitating for many sufferers. We are seeing the same severe symptoms with Long COVID. This strongly suggests that the earlier Ampligen is administered as a therapeutic to both ME/CFS and Long COVID patients, the better the patients’ chances will be.”

For more information about AMP-518, please visit ClinicalTrials.gov and reference identifier

NCT05592418

.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen

^®

(rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit

aimimmuno.com

and connect with the Company on

X

,

LinkedIn

, and

Facebook

.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for ME/CFS or the Post-COVID Condition of Fatigue. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.